Related Experiment Video
Updated: Dec 10, 2025
07:43
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10.9K
Tocilizumab use in COVID-19-associated pneumonia
Alexis K Okoh1, Eliahu Bishburg1, Sagy Grinberg1
1Department of Medicine, Division of Infectious Diseases, Newark Beth Israel Medical Center, Newark, New Jersey, USA.
Journal of Medical Virology
|August 30, 2020
Summary
Tocilizumab (TCB) improved oxygen status in hospitalized COVID-19 patients but did not significantly impact survival rates or other critical outcomes compared to standard care.
Area of Science:
- Immunology
- Critical Care Medicine
- Infectious Diseases
Background:
- Tocilizumab (TCB) is a monoclonal antibody targeting interleukin-6 receptors.
- COVID-19 is a significant global health concern requiring effective treatment strategies.
Purpose of the Study:
- To evaluate the efficacy of tocilizumab (TCB) in hospitalized COVID-19 patients.
- To assess TCB's impact on oxygenation, mortality, septic shock, and acute kidney injury (AKI).
Main Methods:
- A cohort study comparing TCB plus standard care versus standard care alone.
- Propensity score matching (1:2 ratio) was used to create comparable groups.
- Clinical outcomes including oxygen therapy de-escalation, in-hospital death, septic shock, and AKI were analyzed.
Main Results:
- Early TCB administration (within 48 hours) showed improvement in oxygenation in 80% of patients within 7 days.
- No significant differences were observed in in-hospital death, septic shock, or AKI requiring hemodialysis between TCB and no-TCB groups after matching.
- Matched groups included 20 patients receiving TCB and 40 patients not receiving TCB.
Conclusions:
- Early TCB treatment in COVID-19 patients may improve oxygen status during hospitalization.
- TCB did not translate to improved survival or reduced severe complications compared to standard care in this matched cohort.
- Further research may be needed to define TCB's role in COVID-19 management.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
610
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
610
01:28Pneumonia IV: Management
637
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
637
01:22Chronic Obstructive Pulmonary Disease
2.0K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.0K
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.9K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.9K
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.9K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.9K
01:30Asthma-IV: Diagnostic and Management
2.9K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.9K